Silence Therapeutics plc

OTCPK:SLNC.F Stock Report

Market Cap: US$329.7m

Silence Therapeutics Management

Management criteria checks 4/4

Silence Therapeutics' CEO is Iain Ross, appointed in Dec 2025, has a tenure of less than a year. directly owns 0.028% of the company’s shares, worth $92.94K. The average tenure of the management team and the board of directors is 2.3 years and 6.1 years respectively.

Key information

Iain Ross

Chief executive officer

US$482.1k

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.03%
Management average tenure2.3yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Iain Ross's remuneration changed compared to Silence Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025n/an/a

-US$89m

Sep 30 2025n/an/a

-US$65m

Jun 30 2025n/an/a

-US$79m

Mar 31 2025n/an/a

-US$72m

Dec 31 2024US$482kn/a

-US$45m

Sep 30 2024n/an/a

-US$73m

Jun 30 2024n/an/a

-US$50m

Mar 31 2024n/an/a

-US$44m

Dec 31 2023US$512kn/a

-US$54m

Sep 30 2023n/an/a

-US$52m

Jun 30 2023n/an/a

-US$53m

Mar 31 2023n/an/a

-US$53m

Dec 31 2022US$673kn/a

-US$50m

Sep 30 2022n/an/a

-US$40m

Jun 30 2022n/an/a

-US$47m

Mar 31 2022n/an/a

-US$51m

Dec 31 2021US$162kn/a

-US$53m

Sep 30 2021n/an/a

-US$57m

Jun 30 2021n/an/a

-US$57m

Mar 31 2021n/an/a

-US$49m

Dec 31 2020US$2mUS$386k

-US$45m

Sep 30 2020n/an/a

-US$33m

Jun 30 2020n/an/a

-US$28m

Mar 31 2020n/an/a

-US$26m

Dec 31 2019US$122kUS$121k

-US$26m

Compensation vs Market: Iain's total compensation ($USD482.13K) is below average for companies of similar size in the US market ($USD2.29M).

Compensation vs Earnings: Iain's compensation has been consistent with company performance over the past year.

CEO

Iain Ross (71 yo)

less than a year
Tenure
US$482,134
Compensation

Mr. Iain Gladstone Ross, B. Sc (Hons) Biochemistry, C. DIR, CH. D., serves as Executive Chairman at Oxford BioDynamics Plc since 2025. He has been the Non-Executive Director of Tern Plc since October 29, 2...

Leadership Team

NamePositionTenureCompensationOwnership
Iain Ross
Interim CEO & Chairman of the Boardless than a yearUS$482.13k0.028%
$ 92.9k
Rhonda Hellums
Executive VP4.1yrsUS$1.66m0.0011%
$ 3.5k
Steven Romano
Executive VP and Chief Research & Development Officer2.9yrsUS$1.59m0.0092%
$ 30.2k
Marie Lindholm
Chief Scientific Officer2.3yrsno datano data
Gem Hopkins
Head of IR & Corporate Communicationsno datano datano data
Jaimin Shah
SVP & General Counselless than a yearno datano data
Gianine Esposito
Chief Human Resources Officer1.9yrsno datano data
J.P. Gabriel
Chief Technical Operations Officer3.3yrsno datano data
Curtis Rambaran
Chief Medical Officerno datano datano data
2.3yrs
Average Tenure
66yo
Average Age

Experienced Management: SLNC.F's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Iain Ross
Interim CEO & Chairman of the Board6.9yrsUS$482.13k0.028%
$ 92.9k
Rhonda Hellums
Executive VPless than a yearUS$1.66m0.0011%
$ 3.5k
Timothy McInerney
Independent Directorless than a yearno datano data
David Lemus
Independent Non-Executive Director7.8yrsUS$216.07k0.0053%
$ 17.5k
Gordon Duff
Chairman of Scientific Advisory Board6.1yrsno datano data
John Porter
Member of Scientific Advisory Board6.1yrsno datano data
James Ede-Golightly
Directorless than a yearUS$213.07k0.011%
$ 34.9k
Henry Ginsberg
Member of Scientific Advisory Board6.1yrsno datano data
Annemieke Aartsma-Rus
Member of Scientific Advisory Board6.1yrsno datano data
John Whittaker
Member of Scientific Advisory Board5.8yrsno datano data
Tom Brown
Member of Scientific Advisory Board4.2yrsno datano data
6.1yrs
Average Tenure
63yo
Average Age

Experienced Board: SLNC.F's board of directors are considered experienced (6.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/12 04:28
End of Day Share Price 2026/03/09 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Silence Therapeutics plc is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Howard MillerCanaccord Genuity
Keay NakaeChardan Capital Markets, LLC
Nathaniel CallowayEdison Investment Research